drugset / Trial / NCT01907217
Enhancing the Effectiveness of Electroconvulsive Therapy in Severe Depression
Phase 4
Completed
138 enrolled
St Patrick's Hospital, Ireland
Health Research Board, Ireland · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Electroconvulsive therapy (ECT) is the most powerful antidepressant treatment available and is often life-saving. There are concerns, however, that standard bitemporal ECT (the most commonly used form of ECT worldwide) causes persisting retrograde amnesia. However, clinical trials have indicated that high-dose unilateral ECT may be as effective as bitemporal ECT but have much less cognitive side-effects. The trial aims to test the primary experimental hypothesis: High-dose (6 x ST) right unilateral ECT is as effective as (i.e. not inferior to) standard (1.5 x ST) bitemporal ECT for severe depression in terms of Hamilton Depression Rating Score (HDRS) at the end of the treatment course.
Timeline
- Start
- 2008-05
- Primary completion
- 2013-11
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Methohexital | Small molecule | 0.75 mg/kg | — |
| Background | Methohexital | Small molecule | 1 mg/kg | — |
| Background | Suxamethonium | Other / unclassified | 0.5 mg/kg | — |
| Background | Suxamethonium | Other / unclassified | 1 mg/kg | — |